Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smaller incision offer the same cancer surgery outcome?

NCT ID NCT07744087

Disease control Sponsor: Nanfang Hospital, Southern Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This trial compares two surgical techniques for removing tumors near the pancreas (non-pancreatic periampullary adenocarcinomas). One method uses a single small incision plus one extra port, while the other uses the conventional five-port approach. The study will enroll 232 adults who need this surgery and will measure survival rates, complications, and recovery. The goal is to see if the less invasive technique is as effective as the standard procedure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Modified single-incision plus one-port laparoscopic pancreaticoduodenectomy (mSILPD+1)
What this could lead to
If successful, this less invasive surgery could offer a faster recovery and similar survival outcomes compared to the standard approach, potentially becoming a preferred option for eligible patients.
What could go wrong
This is a non-inferiority trial, meaning it aims to show the new method is not worse than the standard. It may not prove superiority, and the single-incision technique could be more challenging or carry different risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 232 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older and younger than 75 years. * Histopathologically confirmed non-pancreatic periampullary carcinoma, or a high clinical suspicion of non-pancreatic periampullary carcinoma when preoperative pathological confirmation is unavailable. * Determined by preoperative multidisciplinary team evaluation to require pancreaticoduodenectomy. * Able to understand and comply with study procedures. * Able and willing to provide written informed consent before any study-specific screening procedure. * Expected to benefit from therapeutic pancreaticoduodenectomy according to applicable clinical guidelines. Exclusion Criteria: * Distant metastasis, including peritoneal, hepatic, distant lymph node, or other organ metastasis. * Requirement for distal, central, or total pancreatectomy, or another palliative procedure. * Preoperative American Society of Anesthesiologists physical status classification of 4 or higher. * Concurrent malignancy other than the target cancer. * Pregnancy or breastfeeding. * Severe psychiatric disorder that would interfere with study participation. * Receipt of neoadjuvant chemotherapy or radiotherapy before surgery. * Vascular invasion requiring vascular resection, as determined by the multidisciplinary team based on preoperative abdominal imaging. * Body mass index greater than 35 kg/m². * Participation in another clinical trial within the previous 3 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ampullary carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

carcinoma of the ampulla of vater distal biliary tract carcinoma duodenal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ampullary carcinoma Distal cholangiocarcinoma Duodenal adenocarcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Nanfang Hospital, Southern Medical University

    RECRUITING

    Guangzhou, Guangdong, 510515, China

  • The People's Hospital of Jianyang City

    RECRUITING

    Jiancheng, Sichuan, 641400, China

  • The Second Affiliated Hospital of Army Medical University (Xinqiao Hospital)

    RECRUITING

    Chongqing, Chongqing Municipality, China

  • West China Hospital, Sichuan University

    RECRUITING

    Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.